Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

Clinical trial NCT01737177 · COMPLETED

Trial details

NCT number: NCT01737177
Sponsor: Fondazione Italiana Linfomi - ETS
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma

Start date: 2012-07-31
Primary completion: 2014-07-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.